Jyoung20 Posted February 23, 2007 Share Posted February 23, 2007 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company developing targeted therapeutics for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that one of its licensees has initiated European clinical trials of a novel anti-cancer agent developed with technology licensed from Peregrine. The investigational drug uses Peregrine's proprietary tumor necrosis therapy (TNT) technology. Peregrine's TNT technology platform targets the DNA that is released by the dead and dying cells found at the center of tumors. TNT-targeted therapies deliver their anti-cancer payload directly to the center of the tumor mass, thereby destroying the tumor "from the inside out," while sparing healthy tissue. Peregrine's radiolabeled TNT agent Cotara® is currently in clinical trials in the U.S. and India for the treatment of glioblastoma multiforme, and a radiolabeled agent using Peregrine's TNT technology for the treatment of lung cancer was recently launched in China. "We believe our TNT technology has considerable potential for targeting anti-cancer therapies, and we are very pleased that one of our licensees has now advanced another TNT anti-cancer agent into clinical trials," said Steven W. King, president and chief executive officer of Peregrine. "The recent launch of a TNT lung cancer therapy by a local firm in China, our new clinical program in India assessing TNT-based Cotara for brain cancer and this clinical debut in Europe make this an exciting time for TNT-based anti-cancer programs." Keeping fingers crossed.. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.